Table of Contents

Articles

• You have access

  Inhibition of Peroxidase Activity of Cytochrome c: De Novo Compound Discovery and Validation

  Ahmet Bakan, Alexandr A. Kapralov, Hulya Bayir, Feizhou Hu, Valerian E. Kagan and Ivet Bahar

  Molecular Pharmacology September 2015, 88 (3) 421-427; DOI: https://doi.org/10.1124/mol.115.097816
• You have access

  Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy

  Natalia Mast, Joseph B. Lin and Irina A. Pikuleva

  Molecular Pharmacology September 2015, 88 (3) 428-436; DOI: https://doi.org/10.1124/mol.115.099598
• You have access

  Sequential Upregulation of Superoxide Dismutase 2 and Heme Oxygenase 1 by tert-Butylhydroquinone Protects Mitochondria during Oxidative Stress

  Jiahong Sun, Xuefang Ren and James W. Simpkins

  Molecular Pharmacology September 2015, 88 (3) 437-449; DOI: https://doi.org/10.1124/mol.115.098269
• You have access

  Chloride is an Agonist of Group II and III Metabotropic Glutamate Receptors

  John O. DiRaddo, Eric J. Miller, Carrie Bowman-Dalley, Barbara Wroblewska, Monica Javidnia, Ewa Grajkowska, Barry B. Wolfe, Dennis C. Liotta and Jarda T. Wroblewski

  Molecular Pharmacology September 2015, 88 (3) 450-459; DOI: https://doi.org/10.1124/mol.114.096420
• You have access

  A Positive Allosteric Modulator of the Adenosine A₁ Receptor Selectively Inhibits Primary Afferent Synaptic Transmission in a Neuropathic Pain Model

  Wendy L. Imlach, Rebecca F. Bhola, Lauren T. May, Arthur Christopoulos and Macdonald J. Christie

  Molecular Pharmacology September 2015, 88 (3) 460-468; DOI: https://doi.org/10.1124/mol.115.099499
• You have access

  cAMP-Dependent Protein Kinase A (PKA)–Mediated c-Myc Degradation Is Dependent on the Relative Proportion of PKA-I and PKA-II Isozymes

  Qingyuan Liu, Eric Nguyen, Stein Døskeland and Évelyne Ségal-Bendirdjian

  Molecular Pharmacology September 2015, 88 (3) 469-476; DOI: https://doi.org/10.1124/mol.115.097915
• You have access

  Lysosomal Sequestration Determines Intracellular Imatinib Levels

  Herman Burger, Alexander T. den Dekker, Sandra Segeletz, Antonius W. M. Boersma, Peter de Bruijn, Maria Debiec-Rychter, Takahiro Taguchi, Stefan Sleijfer, Alex Sparreboom, Ron H. J. Mathijssen and Erik A. C. Wiemer

  Molecular Pharmacology September 2015, 88 (3) 477-487; DOI: https://doi.org/10.1124/mol.114.097451
• You have access

  Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor

  Takanobu Takezako, Hamiyet Unal, Sadashiva S. Karnik and Koichi Node

  Molecular Pharmacology September 2015, 88 (3) 488-501; DOI: https://doi.org/10.1124/mol.115.099176
• You have access

  Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor

  Steven D. Chang, S. Wayne Mascarella, Skylar M. Spangler, Vsevolod V. Gurevich, Hernan A. Navarro, F. Ivy Carroll and Michael R. Bruchas

  Molecular Pharmacology September 2015, 88 (3) 502-511; DOI: https://doi.org/10.1124/mol.115.099150
• You have access

  Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity

  David E. Durrant, Anindita Das, Samya Dyer, Seyedmehrad Tavallai, Paul Dent and Rakesh C. Kukreja

  Molecular Pharmacology September 2015, 88 (3) 512-523; DOI: https://doi.org/10.1124/mol.115.099143
• 

  You have access

  A Resveratrol Analogue Promotes ERK^MAPK–Dependent Stat3 Serine and Tyrosine Phosphorylation Alterations and Antitumor Effects In Vitro against Human Tumor Cells

  Zachary L. Chelsky, Peibin Yue, Tamara P. Kondratyuk, David Paladino, John M. Pezzuto, Mark Cushman and James Turkson

  Molecular Pharmacology September 2015, 88 (3) 524-533; DOI: https://doi.org/10.1124/mol.115.099093